Sign Up to like & get
recommendations!
1
Published in 2019 at "Molecular cell"
DOI: 10.1016/j.molcel.2019.07.012
Abstract: In a recent issue of Cell, Wojtaszek et al. (2019) reported a small-molecule inhibitor of mutagenic translesion DNA synthesis, which targets the interaction between REV1 and REV7, sensitizes cancer cells to cisplatin in vitro and in vivo, and…
read more here.
Keywords:
rev1 pol;
pol inhibition;
inhibition cancer;
cancer ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Clinical Cancer Research"
DOI: 10.1101/2022.09.27.509658
Abstract: DNA polymerase theta (Polθ) is a DNA repair enzyme critical for microhomology mediated end joining (MMEJ). Polθ has limited expression in normal tissues but is frequently overexpressed in cancer cells and, therefore, represents an ideal…
read more here.
Keywords:
radiosensitization;
small molecule;
pol inhibition;
pol inhibitors ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-6190
Abstract: Cancers deficient in homologous recombination (HR) repair secondary to mutations in genes such as BRCA1 or BRCA2, are dependent on alternative DNA damage response (DDR) pathways to maintain genomic integrity, rendering them susceptible to synthetic…
read more here.
Keywords:
inhibition;
pol inhibition;
deficient;
deficient cancers ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms24010319
Abstract: DNA polymerase theta (Polθ)-mediated end joining (TMEJ) is, along with homologous recombination (HR) and non-homologous end-joining (NHEJ), one of the most important mechanisms repairing potentially lethal DNA double-strand breaks (DSBs). Polθ is becoming a new…
read more here.
Keywords:
inhibition;
therapy deficient;
pol inhibition;
anticancer therapy ... See more keywords